Mass General Brigham Ventures
Somerville, Massachusetts, United StatesFounded 2008
Mass General Brigham Ventures is the corporate venture capital arm of the Mass General Brigham health system, founded in 2008 to invest in early-stage life science and healthcare companies emerging from the system's research and innovation pipeline.
Their most common stage is series-b (41% of deals). Average disclosed round size is $58.3M (across 48 rounds with reported amounts).
Portfolio
31
Fund Size
—
Top Stage
Series B
Last 12 Mo
3
Team
AK
Anne Klibanski, MD
President & CEO, Mass General Brigham
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
51 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 InStride Health | Series C | $30M | Jun 2026 |
 InStride | Series C | $30M | Jun 2026 |
| CClaris Bio | Series B | $57M | Jan 2026 |
 Claris | Series B | $118M | Jan 2026 |
 Predicta Biosciences | Series A | $23.4M | Oct 2025 |
 Carta Healthcare | Series B | $18.3M | May 2025 |
 Abcuro, Inc. | Series C | $200M | Feb 2025 |
| RRIPPL Care | Series A | $23M | Oct 2024 |
 Rippl | Series A | — | Oct 2024 |
 InStride Health | Series B | $30M | Mar 2024 |
| InStride Health | Series B | $30M | Mar 2024 |
| Claris | Series A | $57M | Jan 2024 |
| InStride Health | Series B | $30M | Jan 2024 |
| InStride | Series B | $30M | Jan 2024 |
| RRIPPL Care | Series A | $55M | Jan 2024 |
| IInStride Health, Inc. | Series B | $30M | Jan 2024 |
| Rippl | Series A | $55M | Jan 2024 |
| InStride Health | Series B | $30M | Jan 2024 |
 Rome Therapeutics | Series B | $72M | Sep 2023 |
| Carta Healthcare | Series B | $25M | Jun 2023 |
| VViolet Therapeutics Inc. | Seed | $10.6M | May 2023 |
 Amolyt Pharma | Series C | $130M | Jan 2023 |
 Amolyt Pharma | Series C | $138M | Jan 2023 |
| Rippl | Seed | $32M | Sep 2022 |
 Photys | Series A | $75M | Sep 2022 |
Page 1 of 3
Top Co-Investors
General Catalyst15 shared
Valtruis10 shared
.406 Ventures10 shared
Pontifax9 shared
F-Prime Capital8 shared
Novo Capital8 shared
RA Capital Management8 shared
ARCH Venture Partners7 shared
Sofinnova Partners7 shared
Samsara BioCapital7 shared
Sanofi Ventures6 shared
OrbiMed6 shared
Frist Cressey Ventures5 shared
FMZ Ventures5 shared
EQT Life Sciences5 shared
Sectoral Asset Management5 shared
Kurma Partners5 shared
GV4 shared
GG14 shared
New Enterprise Associates4 shared
Last updated: 20 October 2026